LGNDZ OTC
Ligand Pharmaceuticals, Inc.
1W: +19.8%
1M: +42.2%
3M: -77.7%
YTD: -66.5%
$0.00
+0.00 (+33.88%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Balance Sheet Trends
Total Assets
$1.6B
+65.7% ▲
5Y CAGR: +2.8%
Total Liabilities
$543M
+388.1% ▲
5Y CAGR: -3.6%
Shareholders Equity
$1.0B
+22.5% ▲
5Y CAGR: +7.5%
Cash & Investments
$734M
+186.3% ▲
5Y CAGR: +12.3%
Total Debt
$456M
+6313.7% ▲
5Y CAGR: -0.0%
Net Debt
$281M
+530.6% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $20M | $45M | $23M | $72M | $175M |
| Short-Term Investments | $322M | $167M | $147M | $184M | $559M |
| Cash & ST Investments | $341M | $212M | $170M | $256M | $734M |
| Net Receivables | $92M | $35M | $39M | $38M | $60M |
| Inventory | $27M | $13M | $24M | $14M | $9M |
| Other Current Assets | $11M | $8M | $3M | $23M | $30M |
| Total Current Assets | $465M | $264M | $237M | $332M | $832M |
| Property, Plant & Equip. | $33M | $27M | $25M | $25M | $0 |
| Goodwill & Intangibles | $732M | $448M | $470M | $372M | $327M |
| Long-Term Investments | -$240M | $10M | $48M | $11M | $184M |
| Other Non-Current Assets | $272M | $5M | $6M | $203M | $209M |
| Total Non-Current Assets | $833M | $499M | $550M | $610M | $728M |
| Total Assets | $1.3B | $763M | $787M | $942M | $1.6B |
| — Liabilities — | |||||
| Accounts Payable | $8M | $5M | $2M | $5M | $3M |
| Short-Term Debt | $2M | $715K | $410K | $1M | $1M |
| Deferred Revenue | $654K | $355K | $1M | $1M | $0 |
| Other Current Liabilities | $14M | $86M | $8M | $28M | $32M |
| Total Current Liabilities | $42M | $99M | $17M | $37M | $37M |
| Long-Term Debt | $321M | $87M | $0 | $0 | $450M |
| Other Non-Current Liab. | $81M | -$62M | $31M | $34M | -$1M |
| Total Non-Current Liabilities | $435M | $66M | $70M | $74M | $506M |
| Total Liabilities | $476M | $165M | $86M | $111M | $543M |
| — Equity — | |||||
| Common Stock | $17K | $17K | $18K | $20K | $20K |
| Retained Earnings | $449M | $451M | $503M | $499M | $608M |
| Accumulated OCI | -$917K | -$984K | $0 | -$6M | $8M |
| Total Stockholders Equity | $821M | $597M | $701M | $830M | $1.0B |
| Total Liabilities & Equity | $1.3B | $763M | $787M | $942M | $1.6B |
| — Key Metrics — | |||||
| Total Debt | $324M | $88M | $6M | $7M | $456M |
| Net Debt | $305M | $43M | -$17M | -$65M | $281M |
| Total Investments | $322M | $167M | $196M | $195M | $742M |